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Abstract
Background: Protein antigens and their specific epitopes are formulation targets for epitope-
based vaccines. A number of prediction servers are available for identification of peptides that bind
major histocompatibility complex class I (MHC-I) molecules. The lack of standardized methodology
and large number of human MHC-I molecules make the selection of appropriate prediction servers
difficult. This study reports a comparative evaluation of thirty prediction servers for seven human
MHC-I molecules.
Results: Of 147 individual predictors 39 have shown excellent, 47 good, 33 marginal, and 28 poor
ability to classify binders from non-binders. The classifiers for HLA-A*0201, A*0301, A*1101,
B*0702, B*0801, and B*1501 have excellent, and for A*2402 moderate classification accuracy.
Sixteen prediction servers predict peptide binding affinity to MHC-I molecules with high accuracy;
correlation coefficients ranging from r = 0.55 (B*0801) to r = 0.87 (A*0201).
Conclusion: Non-linear predictors outperform matrix-based predictors. Most predictors can be
improved by non-linear transformations of their raw prediction scores. The best predictors of
peptide binding are also best in prediction of T-cell epitopes. We propose a new standard for
MHC-I binding prediction – a common scale for normalization of prediction scores, applicable to
both experimental and predicted data. The results of this study provide assistance to researchers
in selection of most adequate prediction tools and selection criteria that suit the needs of their
projects.
Background
Vaccines are the most effective immunologic intervention
in controlling infectious disease [1] and offer a great
promise for control of emerging infectious disease, cancer,
allergies, and autoimmunity [2]. Peptide-based vaccines
offer means for safe and precisely-directed immune inter-
vention; more than 30 peptide-based vaccines are cur-
rently under development, including several that are in
phase III clinical trials [3]. Most of these vaccines contain
various forms of pathogen-derived or tumor-associated
antigens. Various strategies for formulation (e.g. cells,
whole antigens, subunits, or peptides) as well as for deliv-
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ery systems (e.g. dendritic cells, other antigen presenting
cells, nanoparticles, recombinant viruses, proteins, and
peptides) have been explored in vaccine development [4].
Immunogenic epitopes, the basic immunogenic units
within protein antigens, can be used for precise initiation,
regulation and control of immune responses [3]. Epitope-
based vaccines formulations include peptides (B cell or T-
cell); carbohydrates; epitope-coding DNA or RNA; or
combinations thereof. A targeted strategy for vaccination
focuses on a small number of key antigens and excludes
components that are irrelevant (e.g. self-proteins on can-
cer cells) or have capacity to enhance infection or tumor
growth [3].
T-cell epitopes are peptides that induce immune
responses when bound by major histocompatibility com-
plex (MHC) molecules and presented on the cell surface
for recognition by T-cells of the immune system. Peptides
derived from degradation of internal proteins that bind
MHC-I molecules are recognized by cytotoxic T lym-
phocytes (CTL). Peptides derived from degradation of
external proteins internalized by the antigen presenting
cells and bound by MHC class II molecules are recognized
by T-helper cells (Th). The development of multivalent
vaccines that enable efficient priming, long-lasting and
high magnitude CD8+ T-cell immunity is a major direc-
tion in the current vaccine research [5]. CTL epitopes
induce specific responses against infected or malignant
cells, while Th epitopes initiate and regulate immune
responses.
Antigens from pathogens or tumors represent suitable tar-
gets for immunotherapies and vaccines. Synthetic pep-
tides offer advantages for therapeutic use [6]: they are easy
to produce even for a clinical grade, are free from patho-
gen contamination, have minimal oncogenic potential,
and are chemically stable. Peptide epitopes have been
used in various formulations of vaccines [7-9]. While
some successes of epitope-based cancer vaccines have
been reported [10-12], the clinical applications of
epitope-based vaccines lag behind and the correlation
between responses to T-cell epitopes and clinical out-
comes has not been established [13,14]. The formulations
for cancer immunotherapies include tumor-specific tar-
gets, immune response enhancers, and immune evasion
suppressors [15]. Recent clinical studies indicate that high
level of tumor infiltration by activated CD8+ T-cells com-
bined with a low number of regulatory T-cells (Treg) is a
significant positive prognostic factor for patient survival
in cancers [16-19].
Identification of MHC-binding peptides and their subset
of T-cell epitopes helps improve our understanding of
specificity of immune responses. It is important for dis-
covery of vaccines and immunotherapies [3,6,20]. Tens of
thousands of protein variants have been characterized in
viruses, such as HIV, influenza, or dengue. The numbers
of bacterial, fungal, and parasite antigens are even larger.
Several hundred of tumor-related antigens and their vari-
ants have been reported [21,22]. More than two thousand
variants of human MHC (HLA) have been characterized
to date [23]. Given the significant number of antigens and
their variants, and a large number of HLA variants, sys-
tematic experimental testing of binding capacity of these
peptides is impractical. A number of computational meth-
ods have been developed to facilitate the identification of
MHC binding peptides [24-26]. More than thirty predic-
tion servers have been developed and are accessible via
the Internet. These methods use a variety of statistical and
machine learning approaches making computational pre-
screening of antigens for CTL epitopes a standard
approach in epitope-mapping studies. However, with so
many choices of prediction servers, new questions have
arisen: how to select the best server for a particular HLA
allele; can they be used to predict binding affinity of pep-
tides rather than classify into binders and non-binders;
and how to use predictions to identify T-cell epitopes
amongst HLA ligands? Lack of standards for the develop-
ment of MHC-I binding predictors resulted in servers that
show differences in predictions values and the wide scale
of prediction values. Comparisons of methods for predic-
tion of MHC-binding peptides have been reported, indi-
cating high accuracy of binding predictions [27-29].
Predictions of T-cell epitopes, which are a subset of MHC-
binders are less accurate and more difficult to model than
peptide binding predictions. In a recent study using HLA
class I (HLA-I) transgenic mice, 40 candidate T-cell
epitopes were identified from computational screening of
some 2,900 peptides. Of these 21 were identified as T-cell
epitopes and 17 were high-affinity HLA-binders [30]. A
new generation of predictive models that combine predic-
tions of multiple antigen processing and presentation
steps: HLA binding, peptide binding to transported asso-
ciated with antigen processing (TAP) and predictions of
proteasomal cleavage have been developed (reviewed in
[31]). While combination of HLA predictions and TAP
predictions offers improvement of predictions in some
cases [32], it eliminates TAP-independent peptides from
further analysis, such as those produced by vacuolar [33],
lysosomal [34], or endosomal [35], among others, path-
ways. Proteasomal cleavage predictions are of much lower
accuracy [32] than HLA-binding or TAP-binding predic-
tions; proteasomal cleavage methods have not yet been
adequately validated [31]. The utility and the mode of
usage of combined predictors are yet to be determined. In
the meantime, HLA-binding predictions remain the most
useful computational tools for mapping of HLA ligands
and T-cell epitopes.BMC Immunology 2008, 9:8 http://www.biomedcentral.com/1471-2172/9/8
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Peters et al. [28] developed a community resource bench-
marking prediction on a dataset comprising of 48,828
quantitative peptide-binding affinity measurements.
However, a large fraction of this dataset has already been
employed by some groups to develop their prediction
servers, which may invalidate the comparison with those
that did not employ this dataset. Trost et al. [29], on the
other hand, compared the performance of sixteen servers,
and combined predictions by a number of tools into a
more accurate combined method. Because of the lack of
adequate independent test sets, the comparison studies
performed to date have been based on assessing predictive
performance using pre-defined sets of peptides, rather
than full-overlapping studies of complete antigens. In this
study we compared the performance of 30 servers by first
normalizing the predictions to a common scale and then
assessing the performance using the data from a full-over-
lapping binding study of 9-mer peptides to seven HLA-I
molecules. These peptides were derived from a tumor
antigen and from a fragment of a viral antigen. We com-
pared all the servers to find whether any of them produce
identical predictions. The main part of the study explored
the classification (prediction into binders and non-bind-
ers) vs. peptide binding affinity prediction capabilities of
these servers. We analyzed their prediction performances
on two sets of well-defined T-cell epitopes. Finally we
explored the non-linear issues of post-processing the pre-
diction values as possible means for improving predic-
tions.
Results
Classification
While not all of these servers were designed for the specific
purpose of peptide binding predictions, all of them have
peptide binding predictions implemented as specific
modules. For example MAPPP and ProPred1 predict mul-
tiple steps of antigen processing, MULTIPRED predicts
peptide binding to HLA supertypes, and BIMAS predicts
peptide binding as half-time dissociation (off-rate). Some
servers have advanced options, for example MHCPred
enables the specification of anchor positions. For this
analysis we used the simplest prediction method available
at each server. After performing all predictions using the
test set, we first calculated the Pearson correlation coeffi-
cient for all the servers and found that MAPPP (BIMAS)
and MAPPP (SYFPEITHI) showed identical predictions (r
= 1) to BIMAS and SYFPEITHI, respectively. The ProPred1
and BIMAS predictions showed r ≥ 0.998 for six HLA-I
molecules, r = 0.25 for B*0702, while B*1501 were not
available in ProPred1. This was as expected because
BIMAS and SYFPEITHI matrices were adopted by MAPPP
servers and BIMAS matrices in ProPred1 as HLA-I binding
prediction tools. We therefore excluded MAPPP and
ProPred1 from further analysis. The numbers of the serv-
ers we studied were: A*0201 – 27; A*0301 – 26; A*1101
– 25; A*2402 – 17; B*0702 – 23; B*0801 – 19; and
B*1501 – 12. The mutual analysis of predictors by calcu-
lating correlation coefficient indicates that these predic-
tors are independent, and predict different subsets of
HLA-I binding peptides. These predicted sets are largely
overlapping for predictors that employ similar prediction
algorithm and show very high accuracy, for example
IEDB_ANN and NETM_ANN where r = 0.912.
The analysis of classification accuracy (binders vs. non-
binders) was performed using the cutoff of 30 (measured
binding affinity of ≥ 30% of the binding affinity of a pos-
itive control) for binders, while other peptides were con-
sidered as experimental non-binders. In total 147
individual predictors were tested of which 39 showed
excellent, 47 good, 33 marginal, and 28 poor perform-
ance. The AROC values of these predictions are shown in
Figure 1.
We also performed the analysis of survivin test set and
CMV construct test set and the results were very similar to
the combined set predictions (Figures 2 and 3). The inter-
section values of sensitivity/specificity plots are consistent
with the AROC results. By HLA molecule, the best predic-
tors are for B*0702, where 65% showed excellent classifi-
cation properties, while approximately 30% of predictors
for A*0201, A*0301, and B*1501, and 16% for A*1101
and B*0801 showed excellent classification. The classifi-
cation accuracy for A*2402 is lower than for other HLA
molecules in this study: 18% of predictors showed good
classification properties, and the rest showed marginal or
poor performance.
The best prediction server across all HLA molecules in this
study is NETM_ANN, closely followed by IEDB_ANN and
IEDB_SMM. MHCI_MM, MHCI_SM, MULTI_SVM and
SVMHC_M also perform well. The best predictors we rec-
ommend for classification prediction are shown in Figure
1 as black bars.
Prediction of binding affinity
Prediction scores from various predictors represent a
number of measurable entities. Experimental measure-
ments from the iTopia™ are expressed as the concentration
of peptide needed to achieve 50% binding (ED50 value)
and compared as percentage binding affinity relative to
the positive control peptide. For example, the binding
scores for BIMAS represent off-rates (minutes), IEDB and
NETM_ANN servers represent binding affinity on a
nanomolar scales, MHC I server predicts "binding
energy", while MULTIPRED server predicts an arbitrary
binding score. Large discrepancies are observed even
between predictors from the same server. For example the
survivin1–9  peptide MGAPTLPPA is an experimental
binder to A*0201 with estimated 94% affinity relative toBMC Immunology 2008, 9:8 http://www.biomedcentral.com/1471-2172/9/8
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the positive control. The respective predictions for
IEDB_ANN, IEDB_ARB, and IEDB_SMM are 23441, 365,
and 3237 nM, while NETM_ANN predicted value is 8574
nM. Across all predictors a variety of scales and ranges of
prediction scores have been observed. Obviously these
predictors must be treated as different in silico assays and
the comparison can be made only by using relative scales
of predictions. Using iTopia™ binding assay as the experi-
mental control, we calculated correlation coefficients for
all available predictors for three data sets (survivin, CMV
construct, and the combined data set). The results show
that a high accuracy prediction of peptide binding affinity
can be achieved for A*0201 (Figure 4) where IEDB_ANN
and NETM_ANN show values of r > 0.8 while A*0201 pre-
dictors MHCI_MM, MULTI_ANN, MULTI_SVM,
NETM_WM, and SYFPEITHI showed a relatively high cor-
relation coefficient of 0.8 < r < 0.7. The correlation coeffi-
cients of predictions for other HLA-I alleles are lower
typically 0.6 < r < 0.8 for the best predictors of binding
affinity except for B*0801 where the best predictor had r
= 0.55. Overall, the best predictors of binding affinity are
IEDB_ANN and NETM_ANN. The peptide binding affini-
ties for A*0201 can be predicted in silico with high accu-
racy and, as both the quantity and quality of binding data
increases, this will also be achieved for other HLA-I mole-
cules. The best predictors that we recommend for predic-
tion of peptide binding affinity are marked by asterisks
(Figure 4).
The peptide binding prediction results across three differ-
ent datasets show reasonable consistency for indicating
that the most predictors generalize well (i.e. predict well
across different data sets). For most predictors the predic-
tion accuracy for CMV construct was somewhat higher
than for survivin, while the predictions on the combined
AROC values of predictions using the combined test set for  the 27 servers Figure 1
AROC values of predictions using the combined test 
set for the 27 servers. Black bars designate predictors 
showing the best performance. Vertical axes show the value 
of AROC while horizontal axes show numbers designating 
individual servers, as shown in Table 4.
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AROC values of predictions using survivin test set for the 27  servers Figure 2
AROC values of predictions using survivin test set for 
the 27 servers. Black bars designate predictors showing the 
best performance. Vertical axes show the value of AROC 
while horizontal axes show numbers designating individual 
servers, as shown in Table 4.
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set were mostly higher than those for survivin and lower
than those for CMV construct values. The BIMAS predic-
tions showed low stability in this test, while recom-
mended predictors show high consistency of predictions
across the three test sets.
Non-linear transformations
The predictions of peptide binding classification (Figure
1) show much higher accuracy across different prediction
servers than the predictions of binding affinity (Figure 4).
For example, the three IEDB predictors and two NetMHC
predictors show very similar classification accuracy for
A*0201 (Figure 1) while they show significant differences
in the prediction of peptide binding affinity where ANN-
based predictors are far superior to matrix-based predic-
tors. For each A*0201 predictor, we performed four non-
linear transformations and from five sets data selected one
that showed the best predictive performance.
The results indicate that the scaling of the output results is
a major issue and that it is necessary if linear predictors
(matrix-based) are used for prediction of binding affinity.
Only four predictors were optimized for output scaling
(HLA_LI, IEDB_ANN, PEPC_M, and SVMHC_S), addi-
tional fourteen servers showed minor improvements of
the correlation coefficient (less than 10% increase relative
to the raw predictor output), while the rest of the servers
showed sizable improvements (Figure 5). The largest
improvements were seen for BIMAS, IEDB_ARB,
AROC values of predictions using CMV construct test set for  the 27 servers Figure 3
AROC values of predictions using CMV construct test 
set for the 27 servers. Black bars designate predictors 
showing the best performance. Vertical axes show the value 
of AROC while horizontal axes show numbers designating 
individual servers, as shown in Table 4.
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The correlation coefficients of 27 servers for three datasets Figure 4
The correlation coefficients of 27 servers for three 
datasets. Black bars for survivin, gray bars for the CMV con-
struct, and white bars for the combined set of peptides. Ver-
tical axis shows the value of correlation coefficients while 
horizontal axis shows numbers designating individual servers, 
as shown in Table 4.
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IEDB_SMM, MHCP_I and MHCP_AA predictors. These
results show that most of predictors can be improved by
post-processing the prediction outputs through scaling
and non-linear transformations. This correction will not
affect classification accuracy (binders vs. non- binders)
since classification is threshold-dependent and the rela-
tive order of predictions remains the same as in the raw
prediction list. While all four transformations are repre-
sented in the improved prediction sets, the largest
improvements were achieved by the logarithmic transfor-
mation of matrix predictions indicating that in these cases
inappropriate formula was used for the definition of
matrix coefficients.
Prediction of T-cell epitopes
We performed prediction of peptide binding with tumor
antigen T-cell epitopes and viral epitope sets. Both sets
showed similar prediction patterns and we proceeded
with the analysis of merged data sets. For each server we
predicted the binding affinity of all T- cell epitopes in the
merged set and determined the threshold at which
approximately 90% of the tested T-cell epitopes were pre-
dicted as binders and the threshold at which the first false
positive appears at the test set of binders. The higher of the
thresholds was used for further analysis for the assessment
the number of false positive predictions based on the
number performance on the survivin/CMV construct set.
Predictors could be used for different practical purposes.
We compared the performance of servers in three scenar-
ios for each predictor (representative results are shown in
Tables 1, 2 and 3). These scenarios are represented by the
selection of thresholds which corresponding to practical
application. The first case is the selection of threshold at
which ~90% of T-cell epitopes are predicted as binders;
the second threshold predicts correctly the majority of
binders (31 of 33); and the third threshold does not allow
any non-binders to be predicted as binders. The results
Results of non-linear transformations of the prediction scores for HLA-A*0201 Figure 5
Results of non-linear transformations of the prediction scores for HLA-A*0201. The letters indicate type of trans-
formation that provided the best results: O for original, L for logarithmic, E for exponential, S for square, and R for square 
root. Vertical axis shows the value of AROC while horizontal axis shows numbers designating individual servers, as shown in 
Table 4.
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Table 1: Prediction performance of selected representative servers in order to correctly predict ~90% of T-cell epitopes
Server Thr1 TP (binding) TN (binding) FP (binding) FN (binding) TP (tumor epitopes) TP (viral epitopes)
BIMAS (A) 2 10 143 0 23 76 (89%) 39 (89%)
MHCP_I (A) 100 31 7 136 2 80 (94%) 40 (91%)
IEDB_SMM (B) 1,000 10 143 0 23 77 (91%) 38 (86%)
NHP_CP (C) 0 31 126 17 2 79 (93%) 40 (91%)
IEDB_ANN (D) 10,000 9 143 0 24 76 (89%) 39 (89%)
MULTI_SVM (D) 5.5 6 141 2 27 79 (93%) 41 (93%)
NETM_ANN (D) 10,000 15 143 0 18 80 (94%) 41 (93%)BMC Immunology 2008, 9:8 http://www.biomedcentral.com/1471-2172/9/8
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clearly show that the superior performance, and thus the
selection of the best predictor depend on the practical pur-
pose. For example, NETM_ANN has been judged as the
best overall A*0201 predictor (Figure 1 and Figure 4). This
server also shows the best performance for thresholds that
optimize the selection of T-cell epitopes (Table 1) and the
threshold which does not allow false positive (Table 3),
but it comes as distant second at the threshold that pre-
dicts the vast majority of binders (Table 2). The distinct
best predictor for high sensitivity threshold (Table 2) is
NHP_CP whose overall performance has been assessed as
modest. Overall, considering the balance between false
positive and false negative and prediction of T-cell
epitopes, NETM_ANN is likely to produce the best result
in most cases. The selected thresholds represent the
extreme scenarios (high sensitivity, or high specificity pre-
dictions). In practical applications, the thresholds will be
between these extreme values and costs in terms of false
positives and false negatives can be assessed. The higher
the sensitivity of prediction, the larger the number of false
positives. Conversely, the higher the specificity the lower
the number of true positives.
Further analysis of results (Figure 6) revealed four main
groups of predictors. Group A (BIMAS, MHC_BP, and
NHP_ANN) have the majority of predictions clustered at
the top of the graph with the nearly horizontal trend line.
Although these predictors may provide good prediction of
accuracy with carefully selected threshold, however this
threshold is difficult to determine. The predictions are of
low sensitivity, but relatively high specificity because of a
small numbers of TP and FP, and large numbers of TN and
FN. Group B (IEDB_SMM, IEDB_ARB, MHCP_I and
MHCP_AA) have majority of predictions clustered along
the bottom of the graph with the nearly horizontal trend
line. Again, these predictions may show good classifica-
tion accuracy but it is difficult to identify the appropriate
threshold. The predictions are typically of high sensitivity
and low specificity because of the large number of TP and
FP, and small numbers of TN and FN. Group C numbers
of (MHC_BPS, MULTI_HMM, NHP_CP, PEPDIST, PRE-
DEP, SVMHC_M, and SVMHC_S) have predictions clus-
tered horizontally or as a cloud with the nearly horizontal
trend line. These predictors show moderate accuracy of
predictions irrespective of the selected threshold. Finally,
the remaining predictors form group D which show the
distribution of predictions across the diagonal with a
trend line showing slope from non binders to high bind-
ers. The accuracy of these predictors is moderate to high
with a reasonable balance of TP, TN, FP, and FN. How-
ever, these results need to be taken with a note of caution,
because some of the T-cell epitopes used for the compari-
son are likely to be included in the training sets for server
development. Nevertheless, it is clear that the servers that
are better for prediction of binding affinity are also better
in predicting of T-cell epitopes.
In summary, our results have shown that the best predic-
tors of classification also show the best performance in
prediction of HLA binding affinity, and prediction of T-
cell epitopes, which supports the contention that T-cell
epitopes are more likely to be drawn from the highest
binding affinity peptides [30,36] and for which quantita-
tive theoretical support has been provided recently [37].
Table 2: Prediction performance of selected representative servers in order to correctly predict the majority (95%) of binders
Server Thr2 TP (binding) TN (binding) FP (binding) FN (binding) TP (tumor epitopes) TP (viral epitopes)
BIMAS (A) 0.003 31 105 38 2 84 (99%) 44 (100%)
MHCP_I (A) 1,000 31 7 136 2 80 (94%) 40 (91%)
IEDB_SMM (B) 79,000 31 109 34 2 85 (100%) 44 (100%)
NHP_CP (C) 0 31 126 17 2 79 (93%) 40 (91%)
IEDB_ANN (D) 39,000 31 75 68 2 85(100%) 42 (95%)
MULTI_SVM (D) 3.9 31 101 42 2 84 (99%) 44 (100%)
NETM_ANN (D) 40,000 31 113 30 2 85 (100%) 44 (100%)
Table 3: Prediction performance of selected representative servers in order to exclude all false positives
Server Thr3 TP (binding) TN (binding) FP (binding) FN (binding) TP (tumor epitopes) TP (viral epitopes)
BIMAS (A) 2 10 143 0 23 76 (89%) 39 (89%)
MHCP_I (A) 10 0 143 0 33 2 (2%) 1 (2%)
IEDB_SMM (B) 1,000 10 143 0 23 77 (91%) 38 (86%)
NHP_CP (C) 0.5 6 143 0 27 76 (89%) 40 (91%)
IEDB_ANN (D) 10,000 9 143 0 24 76 (89%) 39 (89%)
MULTI_SVM (D) 5.8 4 143 0 29 75 (88%) 40 (91%)
NETM_ANN (D) 10,000 15 143 0 18 80 (94%) 41 (93%)BMC Immunology 2008, 9:8 http://www.biomedcentral.com/1471-2172/9/8
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Representative graphs for A*0201 binding predictions on T-cell epitopes and the test peptide Figure 6
Representative graphs for A*0201 binding predictions on T-cell epitopes and the test peptide. The thresholds 
marked by broken lines predict approximately 90% of T-cell epitopes and are used for the assessment of false positives and 
false negatives in binding predictions. Representative examples of predictor groups are shown. The x-axis in the left figure rep-
resents experimental scores of test peptides while y-axis represented their scaled predicted scores. The x-axis in the right fig-
ure indicates index of sorted list T-cell epitopes while the y-axis represented their scaled predicted binding scores.
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Conclusions and Discussion
This study shows that major advances have recently been
achieved in the field of computational immunology and
immunoinformatics. These are mainly the results of the
collaborative initiatives that focus on the development of
computational infrastructure for immunology, such as
IEDB or ImmunoGrid. The availability of large high-qual-
ity datasets of HLA ligands and T-cell epitopes and
advanced algorithms enabled the development of
advanced  in silico tools that complement experimental
research and enable screening collections of pathogen
proteomes and large collections of antigens.
We have learnt important lessons about the algorithms
that are used to model HLA-peptide interactions. Non-lin-
ear algorithms, in particular ANNs appear to offer advan-
tage for prediction of peptide binding affinity. Recently
developed algorithms are generally work to be done, since
in silico assays that match contemporary experimental
accuracy are available only for single HLA*0201 9-mer
peptides. We have also identified the problems with some
prediction methods (Figure 6): group A predictors suffer
from low sensitivity and can be improved by re-training
their prediction engines with new data, particularly bind-
ers; group B suffers from low specificity and these models
can be improved by retraining with larger number of non-
binders; group C can be further improved by retraining
with larger number of training data; while group D can be
improved by further improvement of algorithms, while
addition of new data is likely to offer only a small gradual
improvement for this group. The combination of predic-
tions from high-accuracy predictors is likely to be a major
direction for improvement of predictions other than for
A*0201 [29]. A large number of predictors, in particular
those from groups A and B can be improved by post-
processing of raw prediction data, principally non-linear
transformation.
Our results also suggest that normalization of outputs by
scaling onto a common scale (in this study we used the
scale of 0–100) would benefit the field by providing a
standard in silico scale, which would, in turn, enable map-
ping of various experimental methods to a common base
and fair comparison of the results. In this schema, the neg-
ative control peptide maps to 0, while the positive control
peptide maps to 100. Binders of higher affinity than the
positive control will have binding score greater than 100.
The interpretation of the normalized scores is clearer than
the raw scores for examples shown in Table 1, 2, 3. Appro-
priate scaling of outputs also provides practical benefits: a
number of predictors that theoretically have good or
excellent predictive performance when analyzed in fine
detail. However, for those that belong to predictor groups
A, B, or C (Figure 6) it is difficult to determine the best
threshold for classification predictions because the thresh-
old zone between "good" and "poor" predictions is nar-
row, rather than wide as in group D predictors. This makes
predictors in groups A, B, and C inferior to those in the
group D because chances for making poor predictions due
to the sub-optimal, or even poor, selection of prediction
thresholds by users are high.
The fields of computational immunology and immunoin-
formatics [25,38] are growing rapidly. Combining experi-
mental and in silico methods is essential to address
combinatorial problems associated with deciphering
immune responses and the applications such as design of
vaccines and immunotherapies. While identification of
HLA ligands and T-cell epitopes is only a step in the whole
process of translation of basic immunology research into
clinical applications, it is a prime showcase of significant
advances that can be achieved by intelligently combining
wet-lab experimentation with mathematical modeling
and computation.
Methods
We identified 30 servers developed by 19 groups that can
predict HLA-I binding peptides and are accessible through
the Internet (Table 4). The study included several consec-
utive steps: a) Independent experimentally measured test
data sets were identified; b) predictions of peptide bind-
ing were made using up to 30 servers (as available for each
of the seven HLA-I molecules); c) the predictions of indi-
vidual servers were compared whether they are identical
and "duplicate servers" were removed from further analy-
sis; d) predictions were normalized to the common scale
to facilitate comparison of predictive performances; e)
classification accuracy (binders vs. non-binders) was esti-
mated; f) the accuracy of predicted binding affinities was
assessed; g) non-linear transformations of prediction
scores were performed for the improvement of predic-
tions. Predictive algorithms used in these studies include:
binding matrices [39-50], artificial neural networks –
ANN [45,51-54], hidden Markov models – HMM [52],
support vector machines [55-58], structure-based model
[59,60], partial least square function [61], and peptide-
peptide distance function [62].
Data sets
In this study we used data sets produced by the iTopia™
Epitope Discovery System. The two data sets included the
full overlapping study of 134 9-mer peptides spanning the
full length of the tumor antigen survivin (Swiss-Prot:
O15392) [63] and the 42 peptides spanning a 50 amino
acids long construct containing cytomegalovirus (CMV)
internal matrix protein pp65 peptides [64].
These studies produced binding data for eight HLA-I mol-
ecules (HLA-A*0101, -A*0201, -A*0301, -A*1101, -
A*2402, -B*0702, -B*0801, and -B*1501). Only twoBMC Immunology 2008, 9:8 http://www.biomedcentral.com/1471-2172/9/8
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binders within 176 peptides were identified as -A*0101
binders; this molecule was excluded from further study
because of insufficient quantity of test data. For binding/
non-binding classification we considered as positives
those peptides whose binding affinity was ≥ 30% of the
binding affinity of the positive control, as suggested in the
iTopia™ technical information. HLA-A*0201 restricted T-
cell epitopes have been extracted from the literature and
contain 85 well-characterized tumor antigen-related pep-
tides and 44 well-characterized viral T-cell epitopes (see
supplemental materials in Additional file 1). Several pre-
dictors do not have information on specific genotype alle-
les but have predictions for serotypes. For instance, the
prediction results generated by SMM are actually the bind-
ing affinities of peptides to HLA-A2, not exclusively HLA-
A*0201. Such approximation may affect their specificity
in predicting HLA-A*0201 epitopes to some extent. The
data sets used in this study were also deposited in the
Dana-Farber Repository for Machine Learning in Immu-
nology [65].
Predictions and comparisons
The two protein sequences were submitted to the predic-
tion servers and the prediction results were recorded. For
each HLA molecule two prediction applications were ana-
lyzed: classification into binders and non-binders and
prediction of peptide binding affinity. For the assessment
of classification accuracy we used the analysis of the area
under the ROC curve (AROC) [66].
This curve is a plot of the true positive rate TP/(TP+FN) on
the vertical axis vs. false positive rate FP/(TN+FP) on the
horizontal axis for the full range of the decision thresh-
olds. The values AROC≥0.9 indicate excellent,
0.9>AROC≥0.8 good, 0.8>AROC≥0.7 marginal and
0.7>AROC poor predictions [66]. We also used the sensitiv-
ity/specificity plot measure by determining the intersec-
tion point of sensitivity and specificity curves for the
complete range of thresholds. To assess the accuracy of
binding affinity predictions we calculated the Pearson cor-
relation coefficient for experimental measurements X and
a prediction series Y for the studied set of peptides:
xi and   are experimental individual and average affini-
ties;
r
xi xy i y
xi xy i y
xy =
−− ∑
−− ∑ ∑
() ()
() () 22
x
Table 4: List of prediction servers of HLA-I binding peptides, their URLs (as of April 2007), and name abbreviations
ID Servers Abbreviation URLs Prediction algorithm References
1 BIMAS BIMAS [68] Matrix [39]
2 HLA Ligand HLA_LI [69] Matrix [47]
3 IEDB (ANN) IEDB_ANN [70] ANN [54]
4 IEDB (ARB) IEDB_ARB [71] Matrix [48]
5 IEDB (SMM) IEDB_SMM [72] Matrix [49]
6 MAPPP (Bimas) MAPPP_B [73] Matrix [43]
7 MAPPP (SYFPEITHI) MAPPP_S [74] Matrix [43]
8 MHC Binder Prediction MHC_BP [75] Matrix -
9 MHC-BPS MHC_BPS [76] SVM [55]
10 MHC-I (Multiple matrix) MHCI_MM [77] Structure-based model [60]
11 MHC-I (Single matrix) MHCI_SM [78] Structure-based model [60]
12 MHCPred (Interactions) MHCP_I [79] Partial least square [61]
13 MHCPred (Amino Acids) MHCP_AA [80] Partial least square [61]
14 MULTIPRED (ANN) MULTI_ANN [81] ANN [52]
15 MULTIPRED (HMM) MULTI_HMM [82] HMM [52]
16 MULTIPRED (SVM) MULTI_SVM [83] SVM [53]
17 NetMHC (ANN) NETM_ANN [84] ANN [51]
18 NetMHC (Weight Matrix) NETM_WM [85] Matrix [44]
19 nHLAPred (ANNPred) NHP_ANN [86] ANN [53]
20 nHLAPred (ComPred) NHP_CP [87] ANN and Matrix [53]
21 PepDist PEPDIST [88] distance function [57]
22 PeptideCheck (Matrix) PEPC_M [89] Matrix [41]
23 Predep PREDEP [90] Structure-based model [57]
24 ProPred1 PROPRED [91] Matrix [42]
25 Rankpep RANKPEP [92] Matrix [41]
26 SMM SMM [93] Matrix [50]
27 SVMHC (MHCPEP) SVMHC_M [94] SVM [56]
28 SVMHC (SYFPEITHI) SVMHC_S [95] SVM [56]
29 SVRMHC SVRMHC [96] SVM [57]
30 SYFPEITHI SYFPEITHI [97] Matrix [40]BMC Immunology 2008, 9:8 http://www.biomedcentral.com/1471-2172/9/8
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yi and   are individual and average peptide predictions.
For comparisons of two prediction series the same for-
mula was used except that X and Y represent the results of
individual predictions.
To assess the applicability of the prediction servers for
identification of T-cell epitopes we performed predictions
of peptide binding on two sets (tumor antigen and viral
epitopes) of 9-mer HLA-A*0201 restricted T-cell epitopes.
We estimated thresholds that identify ~90% of T-cell
epitopes as positive predictions (TP) and estimated a
number of true positive (TP) false positive (FP), true neg-
ative (TN), and false negative (FN) at that threshold using
predictions based on the analysis of 176 iTopia™ peptides.
Since some of these peptides are well-known, they are
likely included in the training sets for individual servers
and we should interpret these results only as a guide.
Scaling and transformations
To enable visual inspection of prediction comparisons,
both experimental measurements and predictions were
scaled to a common scale from 0 to 100 using linear trans-
formation of the value ranges using the formula for each
value for individual peptide:
where   is the scaled value, ymin is the minimum and ymax
is the maximum value.
Furthermore we performed non-linear transformations of
the raw predicted values from individual servers to assess
whether the scaling and normalization issues affect the
accuracy of predictions. In statistics, the "power trans-
form", also known as "Box-Cox transform" is used to map
data to from one space to another for data stabilization
procedures such as reduction of data variation, improve-
ment of the correlation between variables, and improving
data distribution [67]. We selected four common non-lin-
ear transformations and performed them for each predic-
tor (natural logarithm – L, exponential – E, square – S,
and square root – R functions):
where   is the prediction score for scaled and non-line-
arly transformed value of raw prediction.
The scaled and transformed predictions were assessed to
reveal the predictors have been optimized and those that
can be improved by post-processing of prediction values.
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